Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation:A case report  

作　　者：Fei Xu Meng-Ling Xia Hui-Yun Pan Jiong-Wei Pan Yi-Hong Shen 

机构地区：[1]Department of Respiratory Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310000,Zhejiang Province,China [2]Department of Day Care Ward,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310000,Zhejiang Province,China [3]Department of Respiratory Diseases,Lishui City People’s Hospital,Lishui 323000,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2022年第17期5916-5922,共7页世界临床病例杂志

摘　　要：BACKGROUND Tyrosine kinase inhibitors(TKI)have been the standard first-line therapy for advanced non-small cell lung cancer(NSCLC)of epidermal growth factor receptor(EGFR)sensitive mutations.Uncommon EGFR mutations are increasingly reported with the development of next-generation sequencing.However,their sensitivity to TKIs is variable with limited clinical evidence.CASE SUMMARY Here,we report a patient with the rare delE709_T710insD mutation,who showed the favorable efficacy of dacomitinib and achieved a partial response with a progression-free survival of 7.0 mo.CONCLUSION To our knowledge,this is the first report displaying the clinical efficacy of dacomitinib for patients with delE709_T710insD,which may help to provide alternatives in non-classical variant NSCLC patients.Further studies are warranted to make the optimal choice of EGFR-TKI for rare mutations.

关 键 词：Next-generation sequencing DelE709_T710insD Non-small-cell lung cancer Dacomitinib Uncommon EGFR mutation Case report 

分 类 号：R734.2[医药卫生—肿瘤]